Characterization of Solid Dispersion of Itraconazole Prepared by Solubilization in Concentrated Aqueous Solutions of Weak Organic Acids and Drying

Pharmaceutical Research

Volumn 33, Issue 6, 2016, Pages 1456-1471

  Parikh, Tapan ^a,b   Sandhu, Harpreet K ^c   Talele, Tanaji T ^a   Serajuddin, Abu T M ^a  

^a ST JOHN'S UNIVERSITY   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c Kashiv Pharma   (United States)

Author keywords

acid base interaction; amorphous solid dispersion; Itraconazole; solubilization; stabilization; weak organic acid

Indexed keywords

CARBOXYLIC ACID; CITRIC ACID; GLUTARIC ACID; HYDROGEN; ITRACONAZOLE; MALIC ACID; NANOPARTICLE; TARTARIC ACID; WATER; ANTIFUNGAL AGENT; DICARBOXYLIC ACID; GLUTARIC ACID DERIVATIVE; HYDROCHLORIC ACID; MALIC ACID DERIVATIVE; TARTARIC ACID DERIVATIVE;

AQUEOUS SOLUTION; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; FILTRATION; HYDROGEN BOND; INFRARED SPECTROSCOPY; MEMBRANE FILTER; PARTICLE SIZE; PH; PRECIPITATION; PRIORITY JOURNAL; SOLID DISPERSION; SURFACE AREA; X RAY POWDER DIFFRACTION; CHEMISTRY; CRYSTALLIZATION; DESICCATION; KINETICS; PHARMACEUTICS; POWDER DIFFRACTION; PROCEDURES; SOLUBILITY; X RAY CRYSTALLOGRAPHY;

ANTIFUNGAL AGENTS; CALORIMETRY, DIFFERENTIAL SCANNING; CITRIC ACID; CRYSTALLIZATION; CRYSTALLOGRAPHY, X-RAY; DESICCATION; DICARBOXYLIC ACIDS; DRUG COMPOUNDING; DRUG STABILITY; GLUTARATES; HYDROCHLORIC ACID; HYDROGEN-ION CONCENTRATION; ITRACONAZOLE; KINETICS; MALATES; PARTICLE SIZE; POWDER DIFFRACTION; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TARTRATES; TECHNOLOGY, PHARMACEUTICAL;

EID: 84960110225     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-016-1890-8     Document Type: Article

References (56)

1. Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods. 2000;44(1):235–49.
2. Huang LF, Tong WQ. Impact of solid state properties on developability assessment of drug candidates. Adv Drug Deliv Rev. 2004;56(3):321–34.
3. Selen A, Dickinson PA, Müllertz A, Crison JR, Mistry HB, Cruañes MT, et al. The biopharmaceutics risk assessment roadmap for optimizing clinical drug product performance. J Pharm Sci. 2014;103(11):3377–97.
4. Janssens S, De Zeure A, Paudel A, Van Humbeeck J, Rombaut P, Van den Mooter G. Influence of preparation methods on solid state supersaturation of amorphous SD: a case study with itraconazole and Eudragit E 100. Pharm Res. 2010;27:775–85.
5. Gilis P, De Conde V, Vandecruys R. Beads having a core coated with an antifungal and a polymer. Patent no. WO-94/05263 (A1). 1994.
6. O’Neil M.J. (ed.). The Merck index - an encyclopedia of chemicals, drugs, and biologicals. Whitehouse station, NJ: Merck and Co., Inc., 2006., p. 907
7. Brewster M, Neekens P, Peeters J. Solubilization of itraconazole as a function of cyclodextrin structural space. J Incl Phenom Macrocycl Chem. 2007;57:561–6.
8. Sporanox capsule product information. https://www.janssen.com.au/files/Products/SPORANOX_CAPSULES_PI.pdf (last accessed: 20 July 2015)
9. Beule K. Itraconazole: pharmacology, clinical experience and future development. Int J Antimicrob Agents. 1996;6:175–81.
10. Sporanox oral solution product information. https://www.janssen.com.au/files/Products/SPORANOX_SOLUTION_PI.pdf (last accessed: 20 July 2015)
11. Tao T, Zhao Y, Wu J, Zhou B. Preparation and evaluation of itraconazole dihydrochloride for the solubility and dissolution rate enhancement. Int J Pharm. 2009;367:109–14.
12. Namburi R, Kerr J. Oral itraconazole formulations and methods of making the same. Patent no. US 6,663,897 B2. 2003.
13. Remenar J, Morissette S, Peterson M, Moulton B, MacPhee JM, Guzmán HR, et al. Crystal engineering of novel cocrystals of a triazole drug with 1,4- dicarboxylic acids. J Am Chem Soc. 2003;125:8456–7.
14. Wei S, Mao S, Shi Y, Li L, Fang L. Nanoization of itraconazole by high pressure homogenization: stabilizer optimization and effect of particle size on oral absorption. J Pharm Sci. 2011;24:297–303.
15. Mou D, Chen H, Wan J, Xu H, Yang X. Potent dried drug nanosuspensions for oral bioavailability enhancement of poorly soluble drugs with pH-dependent solubility. Int J Pharm. 2011;413:237–44.
16. Vasanthavada M, Tong WQ, Serajuddin ATM. Development of solid dispersions for poorly water-soluble drug. In: Liu R, editor. Water-insoluble drug formulations. 2nd ed. New York: Informa healthcare; 2008. p. 149–84.
17. Janssens S, de Armas HN, D’ Autry W, Van Schepdael A, Van den Mooter G. Characterization of ternary solid dispersions of itraconazole in polyethylene glycol 6000/ polyvidone- vinylacetate 64 blends. Eur J Pharm Biopharm. 2008;69:1114–20.
18. Baert L, Peeters J, Verreck G. Solid mixtures of cyclodextrins prepared via melt extrusion. Patent no. US 6,365,188 B1, 2002.
19. Mellaerts R, Mole R, Jammaer J, Aerts CA, Paudel A, Van Humbeeck J, et al. Increasing the oral bioavailability of the poorly water soluble drug itraconazole with ordered mesoporous silica. Eur J Pharm Biopharm. 2008;69:223–30.
20. Miller D, DiNunzio J, Yang W, McGinity J, Williams R. Enhanced in vivo absorption of itraconazole via stabilization of supersaturation following acidic to neutral pH transition. Drug Dev Ind Pharm. 2008;34:890–902.
21. Bhardwaj S, Arora K, Kwong E, Templeton A, Clas S, Suryanarayanan R. Correlation between molecular mobility and physical stability of amorphous itraconazole. Mol Pharm. 2013;10:694–700.
22. Sarode A, Sandhu H, Shah N, Malick W, Zia H. Hot melt extrusion for amorphous solid dispersions: temperature and moisture activated drug – polymer interactions for enhanced stability. Mol Pharm. 2013;10:3665–75.
23. Holvoet C, Vander Heyden Y, Plaizier-Vercammen J. Influence of preparation method on itraconazole oral solutions using cyclodextrins as complexing agents. Die Pharmazie. 2007;62(7):510–4.
24. Singh S, Parikh T, Sandhu HK, Shah NH, Malick AW, Singhal D, et al. Supersolubilization and amorphization of a model basic drug, haloperidol, by interaction with weak acids. Pharm Res. 2013;30(6):1561–73.
25. Li S, Wong S, Sethia S, Almoazen H, Joshi YM, Serajuddin ATM. Investigation of solubility and dissolution of a free base and two different salt forms as a function of pH. Pharm Res. 2005;22(4):628–35.
26. Li S, Doyle P, Metz S, Royce AE, Serajuddin ATM. Effect of chloride ion on dissolution of different salt forms of haloperidol, a model basic drug. J Pharm Sci. 2005;94(10):2224–31.
27. Shah A, Serajuddin ATM. Supersolubilization by using nonsalt-forming acid–base interaction. In: Shah N, Sandhu H, Choi D, Chokshi H, Malick AW, editors. Amorphous solid dispersions theory and practice. New York: Springer-Verlag; 2014. p. 595–611.
28. Shah A, Serajuddin ATM. Conversion of solid dispersion prepared by acid–base interaction into free-flowing and tabletable powder by using Neusilin® US2. Int J Pharm. 2015;484(1–2):172–80.
29. Serajuddin ATM, Pudipeddi M. Salt selection strategies. Handbook of pharmaceutical salts - properties, selection and use. Switzerland: Verlag Helvetica Chemica Acta/Wiley–VCH; 2002. p. 158–9.
30. Serajuddin ATM. Salt formation to improve drug solubility. Adv Drug Del Rev. 2007;59(7):603–16.
31. Desiraju GR. Crystal and co-crystal. Cryst Eng Comm. 2003;5:466–7.
32. Li ZJ, Abramov Y, Bordner J, Leonard J, Medek A, Trask AV. Solid-state acid–base interactions in complexes of heterocyclic bases with dicarboxylic acids: crystallography, hydrogen bond analysis, and 15 N NMR spectroscopy. J Am Chem Soc. 2006;128(25):8199–210.
33. Vishweshwar P, Nangia A, Lynch VM. Molecular complexes of homologous alkanedicarboxylic acids with isonicotinamide: X-ray crystal structures, hydrogen bond synthons, and melting point alternation. Cryst Growth Des. 2003;3:783–90.
34. Walsh RDB, Bradner MW, Fleischman S, Morales LA, Moulton B, Rodriguez-Hornedo N, et al. Crystal engineering of the composition of pharmaceutical phases. Chem Commun. 2003;2:186–7.
35. Bis JA, McLaughlin OL, Vishweshwar P, Zaworotko MJ. Supramolecular heterocatemers and their role in cocrystal design. Cryst Growth Des. 2006;6:2648–50.
36. Etter MC. Encoding and decoding hydrogen bonds patterns of organic compounds. Acc Chem Res. 1990;23:120–6.
37. Bis JA, Vishweshwar P, Weyna D, Zaworotko MJ. Hierarchy of supramolecular synthons: persistent hydroxyl…pyridine hydrogen bonds in cocrystals that contain a cyano acceptor. Mol Pharm. 2007;4(3):401–16.
38. Shattock T, Arora K, Vishweshwar P, Zaworotko M. Hierarchy of supramolecular synthons: persistent carboxylic acid-pyridine hydrogen bonds in cocrystals that also contain hydroxyl moiety. Cryst Growth Des. 2008;8(12):4533–45.
39. Qiao N, Li M, Schlindwein W, Malek N, Davies A, Trappitt G. Pharmaceutical cocrystal: an overview. Int J Pharm. 2011;419:1–11.
40. Izutsu KI, Kadoya S, Yomota C, Kawanishi T, Yonemochi E, Terada K. Freeze-drying of proteins in glass solids formed by basic amino acids and dicarboxylic acids. Chem Pharm Bull. 2009;57(1):43–8.
41. Jensen KT, Löbmann K, Rades T, Grohganz H. Improving co-amorphous drug formulations by the addition of the highly water soluble amino acid proline. Pharmaceutics. 2014;6(3):416–35.
42. Lobmann K, Laitinen R, Grohganz H, Strachan C, Rades T, Gordon K. Coamorphous drug systems: enhanced physical stability and dissolution rate of indomethacin and naproxen. Mol Pharm. 2011;8(5):1919–28.
43. Morrision RT, Boyd RN. Organic chemistry. 6th ed. Michigan: Prentice Hall International; 1992.
44. Ober C, Gupta R. Formation of itraconazole-succinic acid cocrystals by gas antisolvent cocrystallization. AAPS PharmSciTech. 2012;13(4):1396–406.
45. Kashchiev D, Van Rosmalen G. Nucleation in solutions revisited. Cryst Res Technol. 2003;38:555–74.
46. Gebauer D, Coelfen H. Prenucleation clusters and non-classical nucleation. Nano Today. 2011;6:564–84.
47. Vekilov PG. Nucleation. Cryst Growth Des. 2010;10:5007–19.
48. Good D, Rodriguez-Hornedo N. Solubility advantage of pharmaceutical cocrystals. Cryst Growth Des. 2009;9:2252–64.
49. Thakuria R, Delori A, Jones W, Lipert M, Roy L, Rodriguez N. Pharmaceutical cocrystals and poorly soluble drugs. Int J Pharm. 2013;453(1):101–25.
50. Shevchenko A, Bimbo LM, Miroshnyk I, Haarala J, Jelínková K, Syrjänen K, et al. A new cocrystal and salts of itraconazole: comparison of solid-state properties, stability and dissolution behavior. Int J Pharm. 2012;436(1):403–9.
51. Hancock BC, Zografi G. The relationship between the glass transition temperature and the water content of amorphous pharmaceutical solids. Pharm Res. 1994;11:471–7.
52. Andronis V, Zografi G. Crystal nucleation and growth of indomethacin polymorphs from the amorphous state. J Non-cryst Sol. 2000;271:236–48.
53. Six K, Verreck G, Peeters J, Binnemans K, Berghmans H, Augustijns P, et al. Investigation of thermal properties of glassy itraconazole: identification of a monotropic mesophase. Thermochim Acta. 2001;376(2):175–81.
54. Parikh T, Gupta SS, Meena AK, Vitez I, Mahajan N, Serajuddin ATM. Application of film casting technique to investigate drug–polymer miscibility in solid dispersion and hot melt extrudate. J Pharm Sci. 2015;104:2142–52.
55. Stevenson CL, Bennett DB, Lechuga‐Ballesteros D. Pharmaceutical liquid crystals: the relevance of partially ordered systems. J Pharm Sci. 2005;94(9):1861–80.
56. Murdande S, Pikal M, Shanker R, Bogner R. Solubility advantage of amorphous pharmaceuticals, part 3: is maximum solubility advantage experimentally attainable and sustainable? J Pharm Sci. 2011;100(10):4349–56.